Screen LibraryBoron nitride nanotubes in nanomedicine /
Saved in:
| Corporate Authors: | |
|---|---|
| Group Author: | ; |
| Published: |
William Andrew is an imprint of Elsevier,
|
| Publisher Address: | Oxford, UK : |
| Publication Dates: | 2016. |
| Literature type: | eBook |
| Language: | English |
| Series: |
Micro and nano technologies
|
| Subjects: | |
| Online Access: |
http://www.sciencedirect.com/science/book/9780323389457 |
| Item Description: | Includes index. |
| Carrier Form: | 1 online resource (246 pages). |
| ISBN: |
9780323389600 0323389600 |
| Index Number: | TA418 |
| CLC: | TB383 |
| Contents: |
Cover; Titile Page; Copyright Page; Contents; List of Contributors; Biographies; Foreword; Chapter 1 -- Introduction to boron nitride nanotubes: synthesis, properties, functionalization, and cutting; 1.1 -- Introduction; 1.2 -- Properties of BNNTs for potential biomedical applications; 1.3 -- Synthesis of BNNTs; 1.3.1 -- Chemical vapor deposition; 1.3.2 -- Ball milling; 1.3.3 -- Laser-based techniques; 1.3.4 -- Large-scale synthesis by plasma-based techniques; 1.4 -- Comparison of production rate, purity, and dispersibility of BNNTs. 1.5 -- Functionalization and cutting of BNNTs for biomedical applications1.5.1 -- Noncovalent functionalization; 1.5.2 -- Covalent functionalization; 1.6 -- Summary; Acknowledgments; References; Chapter 2 -- Functionalization of boron nitride nanotubes for applications innanobiomedicine; 2.1 -- Introduction; 2.2 -- Covalent functionalization; 2.2.1 -- Nitrogen site reaction; 2.2.2 -- Boron site reaction; 2.3 -- Noncovalent functionalization; 2.3.1 -- Small molecules with aromatic groups; 2.3.2 -- Small molecules without aromatic groups; 2.3.3 -- Amino acids; 2.3.4 -- Surfactants; 2.3.5 -- Peptides. 2.3.6 -- Deoxyribonucleic acids (DNA)2.3.7 -- Lipids; 2.3.8 -- Polysaccharides; 2.3.9 -- Polymers; 2.4 -- Defect reaction approach; 2.5 -- Filling BNNTs approach; 2.6 -- Conclusions and perspectives; References; Chapter 3 -- Biocompatibility evaluation of boron nitride nanotubes; 3.1 -- Introduction; 3.2 -- Common methods for evaluating in vitro biocompatibility; 3.2.1 -- Viability and cytotoxicity assays; 3.2.2 -- ROS detection; 3.2.3 -- Apoptosis and necrosis detection; 3.2.4 -- Genotoxicity assessment; 3.3 -- In vitro biocompatibility assessment; 3.4 -- In vivo biocompatibility assessment. 3.5 -- Future studies and perspectives3.6 -- Conclusions; References; Chapter 4 -- Theoretical investigations of interactions between boron nitride nanotubes and drugs; 4.1 -- Introduction; 4.2 -- Density functional theory methods; 4.3 -- BNNTs/biomolecules interactions; 4.3.1 -- BNNTs and platinum-based drugs; 4.3.2 -- BNNTs and heterocyclic compound; 4.3.3 -- BNNTs and other clinically-relevant molecules; 4.3.4 -- BNNTs and amino acids; 4.4 -- Conclusions; References; Chapter 5 -- Boron nitride nanotubes as drug carriers; 5.1 -- Introduction. 5.2 -- Improving the dispersibility of BNNT-based drug carriers5.2.1 -- Oxidation method; 5.2.2 -- Polymer surface modification method; 5.2.3 -- Plasma treatment; 5.2.4 -- Mesoporous silica coating method; 5.3 -- Various drug molecules loaded onto BNNT-based drug carriers; 5.3.1 -- DNA; 5.3.2 -- Proteins; 5.3.3 -- Flavin mononucleotide; 5.3.4 -- Chemotherapy drugs; 5.4 -- Interactions between BNNTs and drug molecules; 5.4.1 -- Weak interactions; 5.4.2 -- Covalent interactions; 5.5 -- Integration of multifunctional properties in BNNT-BASED drug carriers; 5.5.1 -- Targeting release; 5.5.2 -- Imaging. 5.5.3 -- Acting as B carrier for boron neutron capture therapy. |